Back to Results

Zentalis Pharmaceuticals Llc (ZNTL)

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics for cancer treatment in the United States. Its lead candidate, azenosertib, is being studied in a Phase 3 trial for ovarian cancer and other tumor types. The company also has earlier-stage programs, including ZN-c3-001, a Phase 1 study of azenosertib as monotherapy in solid tumors, and MAMMOTH (ZN-c3-006), a Phase 1/2 trial evaluating azenosertib in patients with PARP-inhibitor resistant ovarian cancer. Zentalis has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. The company was incorporated in 2014 and is headquartered in San Diego, California.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-ZNTL
$3.17
2.0% Upside
Fair
$6.89
121.5% Upside
Bargain
Fair
0.0%
November 11, 2026
2.0x
294.4 M
157.5 M
11.2%
79.5%
-7.3
91.8%
Valuation • Fair Value

Zentalis Pharmaceuticals Llc (NASDAQ-ZNTL) Fair Value by Valuation Model

Review the available estimates for Zentalis Pharmaceuticals Llc (NASDAQ-ZNTL), including DCF Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$3.17

Estimated upside of 2.0% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$1.56

Discounted cash flow valuation reference.

Comps Fair Value

$4.38

Comparable-company valuation reference.

Analyst Price Target

$6.89

Analysts imply upside of 121.5%.

How to read these valuation models

Use the 5 available valuation references for Zentalis Pharmaceuticals Llc (NASDAQ-ZNTL) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Zentalis Pharmaceuticals Llc (NASDAQ-ZNTL)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-149.8 M

Current operating profitability reference.

EBITDA Forecast

-178.5 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Zentalis Pharmaceuticals Llc (NASDAQ-ZNTL) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Zentalis Pharmaceuticals Llc (NASDAQ-ZNTL)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

2

Weak quality score that deserves closer review.

Altman Z-Score

-7.3

Lower score that deserves closer risk review.

FCF / Net Income

91.8%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Zentalis Pharmaceuticals Llc (NASDAQ-ZNTL). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Zentalis Pharmaceuticals Llc (NASDAQ-ZNTL)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 11, 2026

Days to Earnings

54

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Zentalis Pharmaceuticals Llc (NASDAQ-ZNTL), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Zentalis Pharmaceuticals Llc (NASDAQ-ZNTL) Stock Forecast & Technical Outlook

Review Zentalis Pharmaceuticals Llc (NASDAQ-ZNTL) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Neutral

The 15-minute technical read for Zentalis Pharmaceuticals Llc (NASDAQ-ZNTL) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for Zentalis Pharmaceuticals Llc (NASDAQ-ZNTL) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Zentalis Pharmaceuticals Llc (NASDAQ-ZNTL) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Zentalis Pharmaceuticals Llc (NASDAQ-ZNTL) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Sell

The monthly technical read for Zentalis Pharmaceuticals Llc (NASDAQ-ZNTL) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Zentalis Pharmaceuticals Llc (NASDAQ-ZNTL)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Buy

Based on the available recommendation mix, Zentalis Pharmaceuticals Llc (NASDAQ-ZNTL) has a Buy consensus, with 5 buy, 5 hold and 0 sell recommendations in the current data set.

Buy 5
Hold 5
Sell 0
FAQ • Fast Investor Answers

Zentalis Pharmaceuticals Llc (NASDAQ-ZNTL) Stock FAQ

Data-supported answers about Zentalis Pharmaceuticals Llc (NASDAQ-ZNTL), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$3.17
Estimated upside 2.0%
Valuation Rating
Near Fair Value
Price is close to fair value
Analyst Target
$6.89
Implied upside 121.5%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Zentalis Pharmaceuticals Llc (NASDAQ-ZNTL) is $3.17. This implies an estimated upside of 2.0% versus the current market price.

Based on the current fair value estimate, the stock is trading close to its estimated fair value.

The available analyst price target for Zentalis Pharmaceuticals Llc (NASDAQ-ZNTL) is $6.89. The analyst target implies estimated upside of 121.5%.

The current financial health read for Zentalis Pharmaceuticals Llc (NASDAQ-ZNTL) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Zentalis Pharmaceuticals Llc (NASDAQ-ZNTL) is November 11, 2026.

The latest available data indicates no current dividend yield for Zentalis Pharmaceuticals Llc (NASDAQ-ZNTL).

The current market capitalization listed for Zentalis Pharmaceuticals Llc is 294.4 M.

The current enterprise value listed for Zentalis Pharmaceuticals Llc is 157.5 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Zentalis Pharmaceuticals Llc is NASDAQ-ZNTL, and the stock is listed on NASDAQ.

Zentalis Pharmaceuticals Llc (NASDAQ-ZNTL) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Zentalis Pharmaceuticals Llc is 11.2%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Zentalis Pharmaceuticals Llc is 79.5%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 466.4 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 208.5 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 186 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 128.8 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 78.353 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 62.595 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 61.522 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 53.245 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 40.928 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 39.9 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 32.055 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 31.841 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 28.748 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.206 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.4 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 24.131 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.214 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.751 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.546 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.864 B